ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовостиTraderScreen

OXFORD BIOMEDICA LS-,50/  GB00BDFBVT43  /

Lang & Schwarz
13.11.2024  23:00:39 Изменение -0.040 Объем сделки Бид23:00:39 Предложение23:00:39 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
4.880EUR -0.81% -
Оборот: -		 4.880Величина цены спроса: - 5.250Величина цены предложения: - 399.03 млнEUR - -
GlobeNewswire 02.09 Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
GlobeNewswire 27.08 Oxford Biomedica to host a free webinar showcasing its AAV expertise
GlobeNewswire 08.08 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 08.08 Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
GlobeNewswire 06.08 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 25.07 Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire 17.07 Oxford Biomedica announces CFO transition
GlobeNewswire 01.04 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 18.03 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 06.03 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 05.03 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 29.01 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 23.01 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 07.01 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 03.01 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 07.12.2023 Business Update
GlobeNewswire 04.12.2023 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 16.11.2023 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 14.11.2023 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 09.11.2023 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 20.09.2023 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 20.09.2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 07.09.2023 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 23.03.2022 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 17.03.2022 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...